Kura Oncology stock: Q3 revenue rises as KOMZIFTI sales expand

Published on 11/10/2026 at 22:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Kura Oncology reported stronger demand for KOMZIFTI in the third quarter. Management also outlined financing and development milestones for 2027 and 2028.

Commercial growth meets funding pressure

KOMZIFTI net product revenue reached 13.9 million US dollars in the third quarter, up 53 percent from the second quarter.
Net loss narrowed to 70.2 million US dollars from 74.1 million US dollars a year earlier.
Cash, cash equivalents and short-term investments stood at 492.1 million US dollars at September 30, 2026.
Kura lowered 2026 collaboration revenue guidance to 40 million to 45 million US dollars while maintaining its 2027 and 2028 ranges.

KURA, US50127T1097, Illustration mit AI erstellt.

Kura Oncology reported third-quarter 2026 results on Tuesday, November 10, highlighting stronger commercial demand for KOMZIFTI and a narrower quarterly loss. The release, carried by StockTitan, said product revenue increased sequentially while collaboration revenue declined from a year earlier.

KOMZIFTI net product revenue reached 13.9 million US dollars in the quarter, up 53 percent from the second quarter. Kura said approximately 150 new patient starts increased 30 percent and total prescriptions exceeded 420, a 65 percent increase from the previous quarter.

Revenue growth and cash position

Total revenue was 22.839 million US dollars for the three months ended September 30, compared with 20.750 million US dollars a year earlier. Collaboration revenue fell to 8.917 million US dollars from 20.750 million US dollars, partly offsetting the commercial contribution from KOMZIFTI.

Net loss narrowed to 70.215 million US dollars from 74.116 million US dollars in the prior-year quarter. Research and development expenses declined to 66.878 million US dollars, while selling, general and administrative expenses fell to 30.248 million US dollars.

Cash, cash equivalents and short-term investments totaled 492.096 million US dollars at September 30, down from 667.240 million US dollars at the end of 2025. Kura also received 55 million US dollars at the closing of an Oberland Capital agreement, consisting of debt and equity financing, while additional funding remains conditional.

Pipeline milestones ahead

Kura said it had reached alignment with the US Food and Drug Administration on a planned registration study of darlifarnib in approximately 40 patients with HRAS-mutated salivary gland cancer. The company targets study initiation in the first half of 2027, while initial topline results from the Phase 3 KOMET-017 program are anticipated in 2028.

The company updated 2026 collaboration revenue guidance to 40 million to 45 million US dollars and maintained its 2027 and 2028 guidance at 90 million to 110 million US dollars for each year. Kura said the guidance reflects non-cash accounting recognition rather than the timing of cash receipts.

Kura Oncology stock traded at 6.82 euros on Lang & Schwarz at 10:54 p.m. CET on Tuesday, November 10, 2026.